Option Care Health Reports Strong Q4/FY2025 Results, Positive 2026 Guidance, and $307M in Share Repurchases

summarizeSummary

Option Care Health delivered solid financial results for the fourth quarter and full year 2025, demonstrating notable growth in net revenue, GAAP diluted EPS, and Adjusted EBITDA. The company's positive momentum is projected to continue into 2026, with strong financial guidance across key metrics including revenue, adjusted EPS, and adjusted EBITDA. Furthermore, the company executed substantial share repurchases totaling $307 million in 2025, actively utilizing the expanded $1 billion buyback program announced in January 2026. This strong performance and positive outlook reinforce the company's market position and operational execution, especially as the stock trades near its 52-week high.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Performance

  The company reported Q4 2025 net revenue of $1,465.4 million (up 8.8%), GAAP diluted EPS of $0.37 (up 5.7%), and Adjusted EBITDA of $126.0 million (up 3.7%). For the full year 2025, net revenue reached $5,649.5 million (up 13.0%), GAAP diluted EPS was $1.27 (up 3.3%), and Adjusted EBITDA was $471.3 million (up 6.2%).

• Positive Full Year 2026 Financial Guidance

  Option Care Health expects 2026 net revenue between $5.8 billion and $6.0 billion, adjusted diluted EPS between $1.82 and $1.92, and Adjusted EBITDA between $480 million and $505 million. Cash provided by operating activities is projected to be at least $340 million.

• Significant Share Repurchases in 2025

  The company repurchased $95 million of stock in Q4 2025, contributing to a total of $307 million in stock repurchases for the full year 2025, demonstrating active execution of its share buyback program.

auto_awesomeAnalysis

Option Care Health delivered solid financial results for the fourth quarter and full year 2025, demonstrating notable growth in net revenue, GAAP diluted EPS, and Adjusted EBITDA. The company's positive momentum is projected to continue into 2026, with strong financial guidance across key metrics including revenue, adjusted EPS, and adjusted EBITDA. Furthermore, the company executed substantial share repurchases totaling $307 million in 2025, actively utilizing the expanded $1 billion buyback program announced in January 2026. This strong performance and positive outlook reinforce the company's market position and operational execution, especially as the stock trades near its 52-week high.